Inspyr Therapeutics Strengthens Clinical Development Capabilities with Appointment of Michael Elliott as Vice President of Clinical Operations
WESTLAKE VILLAGE, Calif., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Inspyr Therapeutics, Inc. (OTCQB:NSPX), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, announced today the appointment of Michael Elliott as Vice President of Clinical Operations. In this newly-created position, Michael will be responsible for managing Inspyr’s clinical trial operations as the company prepares to advance its lead therapeutic Mipsagargin into additional clinical studies for the treatment of cancer.
“As we are planning to begin new clinical trials for Mipsagargin, Michael brings important clinical operations expertise to execute these studies,” said Chris Lowe, Inspyr’s President and Chief Executive Officer. “His experience in selecting and directing clinical sites and service providers, as well as his knowledge of regulatory and CMC standards, strengthens our clinical development capabilities. With Ron Shazer, MD on board as our new Chief Medical Officer and Michael joining to head clinical operations, our team is well equipped to initiate new clinical trials during the first half of next year to advance Mipsagargin as a potential treatment for patients with solid tumors.”
Michael Elliott has two decades of experience in clinical trial management, spanning Phase 1 through pivotal Phase 3 trials, both in the United States and internationally in over 20 countries. Over the course of his career, Mr. Elliott has managed 59 company-sponsored clinical trials and 9 investigator-sponsored trials. Before joining Inspyr, Michael was Senior Director, Clinical Operations at NGM Biopharmaceuticals. In this role, he led the clinical operations group for this company, which has multiple programs studying first-in-class, first-in-human product candidates. Previously, he was Director, Clinical Development at Afferent Pharmaceuticals, a company which was acquired by Merck. Prior to Afferent, he was Director, Clinical Operations at Anthera Pharmaceuticals where he led multiple clinical studies and supported the regulatory submission for a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). Earlier in his career, Michael managed clinical research at Stanford University and the University of California San Francisco. Michael earned a Bachelor of Arts from the University of Pittsburgh and a Master of Arts from Xavier University.
About Inspyr Therapeutics
Inspyr Therapeutics, Inc. is developing a novel technology platform that combines a powerful therapeutic (thapsigargin) with a patented prodrug delivery system that targets the release of drugs within solid tumors. Mipsagargin, its lead drug candidate, has been studied in a Phase 2 clinical trial in patients with advanced hepatocellular carcinoma (liver cancer) and has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in this indication. Mipsagargin is currently being evaluated in Phase 2 clinical studies in patients with glioblastoma (brain cancer), prostate cancer, and clear cell renal cancer. For additional information on Inspyr Therapeutics, visit www.inspyrtx.com.
Cautionary Statement Regarding Forward-Looking Information
This communication may contain forward-looking statements. Investors are cautioned that statements in this document regarding potential applications of Inspyr's technologies or the future prospects of the company constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights and the acceptance of Inspyr’s proposed therapies by the health community. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in Inspyr's periodic reports filed with the Securities and Exchange Commission.
Contact: Tim Tennant Inspyr Therapeutics, Inc. 310-384-9991 email@example.com